Record:   Prev Next
Author Lacouture, Mario E
Title Dermatologic Principles and Practice in Oncology : Conditions of the Skin, Hair, and Nails in Cancer Patients
Imprint Somerset : John Wiley & Sons, Incorporated, 2014
©2013
book jacket
Edition 1st ed
Descript 1 online resource (442 pages)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
Note Cover -- Title page -- Copyright page -- Contents -- List of Contributors -- Preface -- 1: Dermatology and Oncology -- 1: Epidemiology and Burden of Disease -- Introduction -- Dermatologic health in cancer patients and survivors -- Financial burden -- Health-related quality of life -- Dosing of chemotherapy -- Conclusions -- References -- Appendix 1.1 Anticancer agents and associated adverse events affecting the skin, mucosa, hair, and nails. Based on data from Litt JZ, 2009 [8]. -- 2: The History of Supportive Oncodermatology -- Evolution of anticancer therapeutics -- Spectrum of dermatologic adverse events stemming from conventional cytotoxic chemotherapy agents -- Radiation and surgery-induced mucocutaneous toxicities -- Mucocutaneous toxicities induced by novel targeted agents -- Emergence of supportive oncodermatology and future directions -- References -- 3: Structure and Function of the Integumentary System and the Dermatology Lexicon -- Introduction -- Skin -- Epidermis -- Dermal-epidermal junction -- Dermis -- Vasculature -- Nerves -- Subcutaneous tissue -- Appendages -- Eccrine sweat glands -- Apocrine sweat glands -- Sebaceous glands -- Hair -- Nails -- Morphology -- Raised lesions -- Papule -- Plaque -- Nodule -- Cyst -- Wheal -- Depressed lesions -- Erosion -- Ulcer -- Atrophy -- Poikiloderma -- Flat lesions -- Macule -- Patch -- Sclerosis -- Erythema -- Erythroderma -- Fluid-filled lesions -- Vesicle and bulla -- Pustule -- Furuncle -- Abscess -- Surface changes -- Scale -- Crust -- Eschar -- Purpura and vascular lesions -- Purpura -- Infarct -- Shape, configuration, arrangement, and distribution of lesions -- Conclusions -- 4: Types of Dermatologic Reactions -- Exanthematous eruptions -- Urticarial eruptions -- Lichenoid eruptions -- Acneiform eruptions -- Pustular eruptions (acute generalized exanthematous pustulosis)
Bullous eruptions -- Drug-induced vasculitis -- Erythroderma -- Approach to patients with suspected drug eruption -- Step 1: Recognizing the morphology -- Step 2: Associated symptoms and systemic involvement -- Step 3: Histopathologic assessment -- Step 4: Determining the offending drug -- Conclusions -- References -- 5: Grading Dermatologic Adverse Events in Clinical Trials Using CTCAE v4.0 -- Common Terminology Criteria for Adverse Events -- CTCAE grade scale -- Attribution -- Changes in CTCAE V4.0 -- Refined grading to correlate with clinical management -- Alopecia -- Rash acneiform -- Skin hyperpigmentation -- Split of embedded terms -- Rash maculopapular -- Erythroderma -- Bullous dermatitis -- Nail discoloration, nail ridging, and nail loss -- New adverse events -- Hypertrichosis -- Hypohidrosis -- Lipohypertrophy -- Periorbital edema -- Moved to different SOC -- Papulopustular rash -- Rash pustular -- Paronychia -- CTCAE vs. MESTT -- Conclusions -- References -- 6: Psychosocial Issues in Oncology: Clinical Management of Psychosocial Distress, Health-Related Quality of Life, and Special Considerations in Dermatologic Oncology -- Psychosocial distress -- Distress among dermatologic samples -- Dermatologic AEs from cancer treatment -- Risk factors for distress -- Clinical management of distress -- Measuring distress and health-related quality of life in dermatologic oncology -- Psychosocial interventions in oncodermatology -- Conclusions -- References -- 7: Dermatopathology -- Introduction -- Mucocutaneous neoplasms -- Solar (actinic) keratosis -- Squamous cell carcinoma -- Melanocytic tumors -- Inflammatory dermatoses -- Interface (lichenoid) dermatitis -- Spongiotic dermatitis -- Superficial or superficial and deep perivascular lymphohistiocytic inflammation -- Suppurative and granulomatous dermatitis -- Conclusions -- References
2: Cancer-Related Dermatologic Disorders -- 8: Paraneoplastic, Inherited Cancer Syndrome, and Environmental Carcinogen-Related Dermatoses -- Paraneoplastic disorders -- Skin changes from hormone-secreting tumors -- Ectopic ACTH-producing tumors -- Proliferative and inflammatory paraneoplastic dermatoses -- Inherited syndromes with increased cancer risk and skin effects -- Muir-Torre syndrome -- Gardner syndrome -- Cowden syndrome -- Peutz-Jeghers syndrome -- Birt-Hogg-Dubé -- Howel-Evans syndrome -- Hereditary leiomyomatosis/renal cell cancer syndrome -- Environmental carcinogens with increased cancer risk and skin effects -- Arsenic -- Vinyl chloride -- Ionizing radiation -- References -- 3: Dermatologic Conditions During Cancer Therapy -- 9: Oral Mucosal Complications of Cancer Therapy -- Introduction -- Mucosal injury attributable to cytotoxic therapy -- Clinical features and course of mucositis -- Mucositis scoring -- Clinician-based scoring -- Toxicity description and assessment -- Patient management scales -- Research-directed scales -- Variability between mucositis scales -- Patient-reported instruments to assess mucositis severity -- Minimizing inter-observer variability in mucositis assessment -- Impact of mucositis -- Pathobiology of mucositis -- Signal amplification -- Risk factors for mucositis -- The oral environment and mucositis -- Status of the development of therapies for mucositis -- Mucosal changes associated with targeted therapies -- Mucosal injury associated with mTOR inhibitors -- Small molecules and antibodies -- Oral manifestations of graft versus host disease -- Conclusions -- References -- 10: Hair Disorders Associated with Anticancer Agents -- Introduction -- Basic hair anatomy and function -- Types of chemotherapy-induced hair loss/alopecia -- Telogen effluvium -- Anagen effluvium -- Abnormal hair growth
Permanent chemotherapy-induced alopecia -- Radiation-induced alopecia -- Grading scales utilized for determining degree of hair loss or regrowth -- Potential treatments for chemotherapy-induced alopecia -- Prevention of hair loss -- Acceleration of regrowth after chemotherapy -- Conclusions -- References -- 11: Nail Abnormalities in Oncology Practice -- Introduction -- Drugs -- Classic cytotoxic drugs -- Epidermal growth factor receptor inhibitors -- Symptoms -- Nail matrix and nail plate alterations -- Nail fold involvement -- Nail bed involvement -- Digit tip xerosis -- Classification -- Treatment -- Prevention -- Conclusions -- References -- 12: Pruritus -- Introduction -- Cutaneous diseases -- Systemic and psychiatric diseases -- Malignancy -- Therapy -- Clinical findings -- Visual analog scale for pruritus -- Management -- General principles -- Topical treatments -- Systemic treatments -- Physical treatments -- Phototherapy -- Bio-behavioral therapy -- Conclusions -- References -- 13: Management Options for Hot Flashes in Cancer Patients -- Introduction -- Grading of hot flashes -- Treatment of hot flashes -- Pharmacologic interventions -- Nonpharmacologic interventions -- Behavioral therapies -- Physical measures -- Conclusions and recommendations -- References -- 4: Skin Toxicities to Chemotherapy -- 14: Alkylating Agents -- Introduction -- Nitrogen mustards -- Mustargen (mechlorethamine) -- Cyclophosphamide -- Ifosfamide -- Melphalan -- Chlorambucil -- Aziridines and epoxides -- ThioTEPA -- Mitomycin C -- Alkyl sulfonates -- Busulfan -- Nitrosoureas -- Carmustine (bischloroethylnitrosourea) -- Streptozocin -- Hydrazines and triazine derivatives -- Procarbazine -- Dacarbazine -- Temozolomide -- Hydroxurea -- References -- 15: Antimetabolite Reactions -- Introduction -- Methotrexate -- Pemetrexed -- Capecitabine -- Cytarabine -- Gemcitabine
Mercaptopurine -- Thioguanine -- Fludarabine -- Cladribine -- References -- 16: Topoisomerase-Interacting Agents -- Introduction -- Topoisomerase I inhibitors -- Irinotecan and topotecan -- Topoisomerase II inhibitors -- Anthracyclines: Doxorubicin, liposomal doxorubicin, epirubicin and idarubicin -- Etoposide and teniposide -- Mitoxantrone -- Alopecia -- Hand-foot syndrome -- Hyperpigmentation -- Intertrigo -- Nail changes -- Extravasation of topoisomerase inhibitors -- Stevens-Johnson syndrome -- Mucositis -- Radiation recall -- References -- 17: Epidermal Growth Factor Receptor Inhibitor Reactions -- Introduction -- Epidermal growth factor receptor inhibitors -- Dermatologic adverse events of EGFRIs -- Papulopustular (acneiform) rash -- Xerosis and pruritus -- Hyperpigmentation -- Telangiectasias -- Mucosal toxicities -- Hair alterations -- Nail and periungual involvement -- Interaction of EGFRIs with conventional cytotoxic chemotherapy and radiotherapy -- Conclusions -- References -- 18: Small Molecule Multikinase Inhibitors -- Introduction -- Kit, PDGFR and bcr-abl inhibitors: imatinib, nilotinib, dasatinib -- Drugs, indications, and mechanisms of action -- Antiangiogenic agents: sorafenib, sunitinib axitinib, regorafenib, and pazopanib -- Hand-foot skin reaction -- Subungual splinter hemorrhages -- Erythematous rashes -- Hair modifications -- Xerosis -- Genital involvement -- Mucositis -- AEs specifically related to sunitinib -- AEs related specifically to sorafenib -- mTOR inhibitors: everolimus and temsirolimus -- Drugs and mechanisms of action -- Skin manifestations -- Conclusions -- References -- 19: Antimicrotubule Agents -- Introduction -- Taxanes -- Clinical features -- Treatment of choice and prognosis -- Vinca alkaloids -- Clinical features -- Treatment of choice and prognosis -- Estramustine phosphate sodium -- References
20: Histone Deacetylase Inhibitors, Proteasome Inhibitors, Demethylating Agents, Arsenicals, and Retinoids
List of Contributors, vii Preface, x Section 1 Dermatology and Oncology 1 Epidemiology and Burden of Disease, 3Beth N. McLellan, Devika Patel and Mario E. Lacouture 2 The History of Supportive Oncodermatology, 17Yevgeniy Balagula, Steven T. Rosen and Mario E. Lacouture 3 Structure and Function of the Integumentary System and the Dermatology Lexicon, 24Emmy Graber and Amit Garg 4 Types of Dermatologic Reactions, 33Raed O. Alhusayen, Sandra R. Knowles and Neil H. Shear 5 Grading Dermatologic Adverse Events in Clinical Trials Using CTCAE v4.0, 47Alice Chen, Asha Acharya and Ann Setser 6 Psychosocial Issues in Oncology: Clinical Management of Psychosocial Distress, Health-Related Quality of Life, and Special Considerations in Dermatologic Oncology, 60Lynne I. Wagner and David Cella 7 Dermatopathology, 69Molly A. Hinshaw and James L. Troy Section 2 Cancer-Related Dermatologic Disorders 8 Paraneoplastic, Inherited Cancer Syndrome, and Environmental Carcinogen-Related Dermatoses, 77Cindy England Owen and Jeffrey P. Callen Section 3 Dermatologic Conditions During Cancer Therapy 9 Oral Mucosal Complications of Cancer Therapy, 89Stephen T. Sonis 10 Hair Disorders Associated with Anticancer Agents, 100Caroline Yeager and Elise A. Olsen 11 Nail Abnormalities in Oncology Practice, 115Robert Baran, Bernard Fouilloux and Caroline Robert 12 Pruritus, 122Tejesh Patel and Gil Yosipovitch 13 Management Options for Hot Flashes in Cancer Patients, 131Amanda R. Moraska and Charles L. Loprinzi Section 4 Skin Toxicities to Chemotherapy 14 Alkylating Agents, 147Elisabeth Livingstone, Lisa Zimmer, Larissa Leister and Dirk Schadendorf 15 Antimetabolite Reactions, 160Emily Y. Chu and Heidi H. Kong 16 Topoisomerase-Interacting Agents, 170Tomas Skacel, Roger von Moos and Reinhard Dummer 17 Epidermal Growth Factor Receptor Inhibitor
Reactions, 184Yevgeniy Balagula and Mario E. Lacouture 18 Small Molecule Multikinase Inhibitors, 196Caroline Robert, Vincent Sibaud and Christine Mateus 19 Antimicrotubule Agents, 208Claus Garbe 20 Histone Deacetylase Inhibitors, Proteasome Inhibitors, Demethylating Agents, Arsenicals, and Retinoids, 215Najla Al-Dawsari, Shannon C. Trotter and Francine Foss 21 Miscellaneous Reactions, 224Katharina C. Kaehler, Christine B. Boers-Doets, Mario E. Lacouture and Axel Hauschild 22 Skin Toxicities due to Biotherapy, 233Kathryn T. Ciccolini, Katharina C. Kaehler, Mario E. Lacouture and Axel Hauschild 23 Monoclonal Antibodies, 241Caroline Robert 24 Endocrine Agents, 248Katherine Szyfelbein Masterpol, Maura Dickler and Mario E. Lacouture 25 Agents for the Management of Hematologic Reactions, 257Mee-young Lee and Caroline C. Kim 26 Radiation-Induced Skin Reactions, 264Rebecca K.S. Wong and Zahra Kassam 27 Hematopoietic Stem Cell Transplantation and Graft Versus Host Disease, 281Stephanie W. Hu and Jonathan Cotliar 28 Extravasation Reactions, 295Seppo W. Langer 29 Topical Anticancer Therapies, 301Patricia L. Myskowski 30 Life-threatening (Serious) Dermatologic Adverse Events, 310Milan J. Anadkat 31 Dermatologic Infections, 319Yevgeniy Balagula, Mario E. Lacouture and James I. Ito Section 5 Late Cutaneous Events from Cancer Treatment 32 Late Dermatologic Conditions, 339Jennifer Nam Choi Section 6 Dermatologic Practice in Oncology 33 Management Algorithms for Dermatologic Adverse Events, 367Alyx Rosen, Iris Amitay-Laish and Mario E. Lacouture 34 Dermatologic Therapeutics and Formulations, 384Judy H. Borovicka, Jennifer R.S. Gordon, Ann Cameron Haley, Nicole E. Larsen and Dennis P. West 35 Dermatologic Techniques and Procedures, 401Robert Eilers Jr., Kishwer S. Nehal and Erica H. Lee 36 Appearance-Related Concerns in the
Cancer Patient, 410Amy J. Derick Index, 417
Description based on publisher supplied metadata and other sources
Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2020. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries
Link Print version: Lacouture, Mario E. Dermatologic Principles and Practice in Oncology : Conditions of the Skin, Hair, and Nails in Cancer Patients Somerset : John Wiley & Sons, Incorporated,c2014 9780470621882
Subject Skin -- Diseases -- Etiology.;Skin -- Diseases -- Psychology.;Tumors -- Complications
Electronic books
Record:   Prev Next